Edwards Lifesciences Corp — Director's Dealing 2017

May 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2017-05-11

Reporting Person: Zovighian Bernard J (CVP, Surgical Heart Valves)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-11	Common Stock	A	2550.0000	$0.0000	Acquired	12102.4816	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-11	Employee Stock Option (Right to Acquire)	$110.2500	A	22400.0000	Acquired	2024-05-10	Common Stock (22400.0000)	Direct
2017-05-11	Performance Rights	$	A	3175.0000	Acquired		Common Stock (3175.0000)	Direct

Footnotes

F1: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

F3: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F4: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.